Tazverik Drug Interactions

Effect of Other Drugs on TAZVERIK: Strong and Moderate CYP3A Inhibitors: Co-administration of TAZVERIK with a strong or moderate CYP3A inhibitor increases tazemetostat plasma concentrations [see Pharmacology: Pharmacokinetics under Actions], which may increase the frequency or severity of adverse reactions. Avoid co-administration of strong or moderate CYP3A inhibitors with TAZVERIK. If co-administration of moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose [see Dosage Modifications for Drug Interactions under Dosage & Administration].
Strong and Moderate CYP3A Inducers: Co-administration of TAZVERIK with a strong or moderate CYP3A inducer may decrease tazemetostat plasma concentrations [see Pharmacology: Pharmacokinetics under Actions], which may decrease the efficacy of TAZVERIK. Avoid co-administration of moderate and strong CYP3A inducers with TAZVERIK.
Effect of TAZVERIK on Other Drugs: CYP3A Substrates: Co-administration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates [see Females and Males of Reproductive Potential under Use in Pregnancy & Lactation; Pharmacology: Pharmacokinetics under Actions].